Literature DB >> 7949203

Aromatase inhibitors--mechanisms of steroidal inhibitors.

R W Brueggemeier1.   

Abstract

Inhibition of aromatase has been an attractive approach for examining the roles of estrogen biosynthesis in various physiological or pathological processes. Effective aromatase inhibitors can serve as potential therapeutic agents for controlling estrogen-dependent diseases such as hormone-dependent breast cancer. Investigations on the development of aromatase inhibitors have therefore expanded greatly in the past two decades. Numerous steroidal agents have been developed that have high affinities for the aromatase enzyme complex and exhibit either competitive inhibition, irreversible inhibition, or mechanism-based (enzyme-activated) inhibition. Mechanism-based inhibitors have distinct advantages in drug design, since these inhibitors are highly enzyme specific, produce prolonged inhibition, and exhibit minimal toxicities. Examination of the structure-activity relationships of the numerous steroidal aromatase inhibitors suggest that the spacial requirements for interaction of agents with the active site of aromatase are very restrictive, permitting only small structural changes to be made on the A-ring and at C-19. Incorporation of small polar substituents at the C-4 position, such as a hydroxyl group, or addition of aryl functionalities at the 7 alpha-position of the steroid, are the exceptions, and inhibitors with such modifications exhibit enhanced affinity for the enzyme. Future investigations of steroidal aromatase inhibitors as probes of the active site of purified aromatase will provide valuable information on enzyme structure at the molecular level, will permit a more detailed examination of the mechanisms of inhibition, and will enhance the development of more specific and effective inhibitors for the treatment of estrogen-dependent breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949203     DOI: 10.1007/bf00682739

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  61 in total

Review 1.  Biochemical and molecular aspects of aromatase.

Authors:  R W Brueggemeier
Journal:  J Enzyme Inhib       Date:  1990

2.  Interactions of thiol-containing androgens with human placental aromatase.

Authors:  P J Bednarski; S D Nelson
Journal:  J Med Chem       Date:  1989-01       Impact factor: 7.446

3.  Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

Authors:  M Dowsett; D C Cunningham; R C Stein; S Evans; L Dehennin; A Hedley; R C Coombes
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

4.  1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis.

Authors:  D Henderson; G Norbisrath; U Kerb
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

5.  Potent enzyme-activated inhibition of aromatase by a 7 alpha-substituted C19 steroid.

Authors:  C E Snider; R W Brueggemeier
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

6.  7 alpha-substituted derivatives of androstenedione as inhibitors of estrogen biosynthesis.

Authors:  M V Darby; J A Lovett; R W Brueggemeier; M P Groziak; R E Counsell
Journal:  J Med Chem       Date:  1985-06       Impact factor: 7.446

7.  Synthesis and biochemical studies of 7-substituted 4,6-androstadiene-3,17-diones as aromatase inhibitors.

Authors:  P K Li; R W Brueggemeier
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

8.  Studies on aromatase inhibition with 4-androstene-3,6,17-trione: its 3 beta-reduction and time-dependent irreversible binding to aromatase with human placental microsomes.

Authors:  M Numazawa; M Tsuji; A Mutsumi
Journal:  J Steroid Biochem       Date:  1987-09       Impact factor: 4.292

9.  Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.

Authors:  L Y Wing; W M Garrett; A M Brodie
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

10.  Inactivation of human placental aromatase by 6 alpha- and 6 beta-hydroperoxyandrostenedione.

Authors:  L Tan; A Petit
Journal:  Biochem Biophys Res Commun       Date:  1985-04-30       Impact factor: 3.575

View more
  7 in total

Review 1.  The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

Authors:  Mohamed F M Mitwally; Robert F Casper; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-10-04       Impact factor: 5.211

Review 2.  Aromatase inhibitors: past, present and future in breast cancer therapy.

Authors:  Udayan Dutta; Kartikeya Pant
Journal:  Med Oncol       Date:  2007-11-01       Impact factor: 3.064

Review 3.  Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.

Authors:  Paul E Goss; Kathrin Strasser
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.

Authors:  Mark Wormke; Matthew Stoner; Bradley Saville; Kelcey Walker; Maen Abdelrahim; Robert Burghardt; Stephen Safe
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

Review 5.  The role of aromasin in the hormonal therapy of breast cancer.

Authors:  Magdolna Dank
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

6.  Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.

Authors:  Muaiad Kittaneh; Stefan Glück
Journal:  Breast Cancer (Auckl)       Date:  2011-10-09

Review 7.  Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.

Authors:  Maxwell R Lloyd; Seth A Wander; Erika Hamilton; Pedram Razavi; Aditya Bardia
Journal:  Ther Adv Med Oncol       Date:  2022-07-30       Impact factor: 5.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.